% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • insidetrack22 insidetrack22 Oct 26, 2012 11:31 AM Flag

    Too premature to panic. Selling now is plain stupid.

    Imgn long term outlook is unchanged. Imgn has over $200MM in cash, strong pipeline of products, and an excellent outlook on TD-M1 FDA approval in the near future. Imgn has no debt and money spent was for a good reason (drug trials, formulation development). Imgn is building a solid foundation poised for future growth. I don't see an issue here. For the next quarter earning, analyst has set the bar real low (-0.87) so what is the big deal of (-0.30) today? The bottom line is: Imgn TD-m1 data looks fantastic, will get FDA approval, and since TD-M1 platform is so flexible, revenue from numerous partnerships will materilaize which makes current Roche partnership looks like a drop in the revenue bucket. Long term outlook will be that IMGN will have significant products coming into market with long term revenue streams. Today price drop is over-reaction from short sighted investors.If I had a $1MM now, I'll bet it all on IMGN today.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
9.96-0.290(-2.83%)Apr 24 4:00 PMEDT